Maia Biotechnology wins $2.3 million NIH grant for Phase 2 NSCLC trial expansion
MAIA•FDA clearance for amended IND
The company also said it secured FDA clearance for an amended IND for ateganosine, citing improved manufacturing capabilities and efficiencies.
NIH grant to support Phase 2 expansion
Maia Biotechnology secured a USD 2.3 million grant from the National Institutes of Health to fund a U.S. Phase 2 expansion in third-line non-small cell lung cancer (NSCLC).
